ReviewThe American journal of tropical medicine and hygiene2025
Intravenous Levosimendan for Acute Heart Failure with Renal Impairment Following Severe Scorpion Envenomation: Case Report and Literature Review.
Review in The American journal of tropical medicine and hygiene, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute heart failure, presenting as either cardiogenic shock or pulmonary edema, is the main cause of mortality because of scorpion envenomation (SE) in many tropical and subtropical parts of the world. Standard heart failure treatment, including inotropes and diuretics to treat cardiogenic shock and pulmonary edema, was used in most studies. However, the role of the inotrope levosimendan in the treatment of cardiogenic shock complicated by pulmonary edema and renal impairment after SE has rarely been reported, to the best of our knowledge. Here, we report this case of severe SE complicated by cardiogenic shock and pulmonary edema successfully managed with levosimendan in a 4-year-old patient. As a consequence, the use of this inotropic drug seems to be beneficial in severe cases of SE complicated by severe cardiogenic shock and not stabilized by the usually used inotropic and vasopressor agents (dobutamine and noradrenaline). Further studies are needed to confirm the usefulness of levosimendan in cardiogenic shock related to severe SE.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.